Unjha Formulations Adjusts Evaluation Amid Mixed Financial Performance and Market Challenges

Unjha Formulations, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a mildly bearish stance to a mildly bullish outlook.
The stock's current price stands at 25.55, showing a notable increase from the previous close of 23.60. Over the past week, Unjha Formulations has outperformed the Sensex, with a return of 8.77% compared to the index's decline of 0.53%. However, the stock has faced challenges over longer periods, with a year-to-date return of -15.93% and a one-year return of -23.27%, indicating a significant underperformance relative to the broader market.

Key financial metrics reveal a weak long-term fundamental strength, highlighted by a -1.02% CAGR growth in operating profits over the last five years. The company's ability to service its debt appears limited, as evidenced by a low EBIT to Interest ratio of 0.34. Additionally, Unjha Formulations has reported flat financial performance for the quarter ending June 2025, with net sales declining by 30.08%.

Overall, the adjustment in evaluation reflects the complex dynamics at play for Unjha Formulations, as it navigates a challenging market landscape.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.